

STUDY TITLE	Asian registry of the BioFreedom BA9 Drug-Coated Coronary Stent for patients with ST elevation myocardial infarct (STEMI) undergoing percutaneous coronary intervention (PCI)
STUDY POPULATION	Patients with ST elevation myocardial infarct (STEMI) undergoing percutaneous coronary intervention (PCI)
PRINCIPAL INVESTIGATOR	Dato' Dr. Amin Ariff Nuruddin
STUDY COORDINATOR	Renobastian Nur Syamsi Contact number : 03 – 2617 8200 Ext: 3205
START DATE	01 November 2018
END DATE	31 March 2021
INCLUSION	<ul style="list-style-type: none"> • STEMI patients treated with one or several BioFreedom stent(s) within 12h of symptom onset • Patients who agree to comply with the follow up requirements. • Patients with a life expectancy of > 1 year at time of consent. • Patients in cardiogenic shock • Any out of hospital cardiac arrest • Glasgow score < 15 • Patients unable or unwilling to give documented informed consent • Patients with any PCI 6 months prior to the baseline procedure
EXCLUSION	<ul style="list-style-type: none"> • Patients eligible to receive dual anti platelet therapy (DAPT). The establishment of the DAPT regimen is at the physician's discretion. • Patients taking part in another interventional trial which has not completed follow-up for the primary endpoint • Patient has received an additional stent different from a BioFreedomBA9 (SS) DCS stent during the index procedure. • Pregnant or breastfeeding women